Human Recombinant LEPR
Reference ID:KB-2394
Western Blot
Flow Cytometry
Gene of Interest
Gene Synonyms:LEPR;DB;OBR
Protein Names:Leptin receptor (LEP-R) (HuB219) (OB receptor) (OB-R) (CD antigen CD295)
Accession Data
Organism:Homo sapiens (Human)
Mass (kDa):1324.94
Length (aa):1165
Proteomics (Proteome ID):UP000005640
Proteomics (Chromosome): Chromosome 1
Function [CC]:Receptor for hormone LEP/leptin (Probable) (PubMed:22405007). On ligand binding, mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides, also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones (By similarity) (PubMed:9537324). In the periphery, increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity (PubMed:25060689, PubMed:12504075, PubMed:8805376). Control of energy homeostasis and melanocortin production (stimulation of POMC and full repression of AgRP transcription) is mediated by STAT3 signaling, whereas distinct signals regulate NPY and the control of fertility, growth and glucose homeostasis. Involved in the regulation of counter-regulatory response to hypoglycemia by inhibiting neurons of the parabrachial nucleus. Has a specific effect on T lymphocyte responses, differentially regulating the proliferation of naive and memory T -ells. Leptin increases Th1 and suppresses Th2 cytokine production (By similarity). {ECO:0000250|UniProtKB:P48356, ECO:0000269|PubMed:12504075, ECO:0000269|PubMed:22405007, ECO:0000269|PubMed:25060689, ECO:0000269|PubMed:8805376, ECO:0000269|PubMed:9537324, ECO:0000305|PubMed:25232147}.; Isoform A: May transport LEP across the blood-brain barrier. Binds LEP and mediates LEP endocytosis. Does not induce phosphorylation of and activate STAT3. {ECO:0000250|UniProtKB:P48356}.; Isoform E: Antagonizes Isoform A and isoform B-mediated LEP binding and endocytosis. {ECO:0000250|UniProtKB:P48356}.
Tissue Specificity:Isoform A is expressed in fetal liver and in hematopoietic tissues and choroid plexus. In adults highest expression in heart, liver, small intestine, prostate and ovary. Low level in lung and kidney. Isoform B is highly expressed in hypothalamus, but also in skeletal muscle. Detected in fundic and antral epithelial cells of the gastric mucosa (PubMed:19159218). Isoform B and isoform A are expressed by NK cells (at protein level) (PubMed:12504075). {ECO:0000269|PubMed:12504075, ECO:0000269|PubMed:16052473, ECO:0000269|PubMed:19159218}.
Disease:Leptin receptor deficiency (LEPRD) [MIM:614963]: A rare disease characterized by normal levels of serum leptin, hyperphagia and severe obesity from an early age. Additional features include alterations in immune function, and delayed puberty due to hypogonadotropic hypogonadism. {ECO:0000269|PubMed:25751111, ECO:0000269|PubMed:9537324}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Mutagenesis:MUTAGEN 986 986 Y->F: Greatly reduced PTPN11 binding; no PTPN11 phosphorylation; no effect on STAT3 phosphorylation. {ECO:0000269|PubMed:9600917}.; MUTAGEN 1078 1079 YY->FF: No effect on PTPN11 nor STAT3 phosphorylation. {ECO:0000269|PubMed:9600917}.; MUTAGEN 1141 1141 Y->F: No effect on PTPN11 phosphorylation; no STAT3 phosphorylation. {ECO:0000269|PubMed:9600917}.
Reagent Data
Molecular Weight:16.24
Features:Soluble in water and most aqueous buffers above and below the isoelectric point.
Formulation:Sterile filtered and Dialyzed prior to lyophilization
Formulation Concentration:Dialyzed against 45 mM sodium bicarbonate
Buffer Volume:Standard
Buffer Solution:PBS
Endotoxin Level:< 1%
Aggregate Tested By:SDS-PAGE
Endotoxin Screened:< 0.1 ng/ug
Purity:> 95%
Determined: SDS-PAGE
Validated: RP-HPLC
Sample Handling
Stability:This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.
Preparation:Reconstitute in sterile distilled H2O to no less than 100 ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.